



New Therapies for Pancreatitis

Meet three leaders at the
forefront of innovation



**John
Mellnik**

CEO,
Path BioAnalytics



**Tony
Kolton**

CEO,
Regenerative
Medical Solutions



**Dena
Cohen**

CSO,
Regenerative
Medical Solutions

Mission:Cure

Agenda

Welcome

Megan Golden

Introduction to Mission Cure Capital

Linda Martin

Conversation with Industry Leaders

John Mellnik (PBA),
Tony Kolton & Dena Cohen (RMS)

Q&A

Mission: Cure Team

Mission:Cure

Our Story



Eric and Megan




Amy and Linda

SEEKING RELIEF FROM PANCREATITIS PAIN
Mission:Cure


Introduction to Mission Cure Capital




Mission Cure Capital
INVESTING TO CURE PANCREATITIS



Goal: to accelerate effective, life-changing treatments and cures for pancreatitis



Investment criteria: high impact, commercially-promising treatments for pancreatitis or its symptoms



Progress: 5 investments driving progress on multiple disease mechanisms and pathways

Mission:Cure



Mission Cure Capital
INVESTING TO CURE PANCREATITIS



Pancreatitis stops kids (and adults) from having normal lives.

With impact investors and innovative scientific partners, we ~~can change~~ **are changing** this.

MCC is the **first** and **only** impact investment firm **focused on pancreatitis** through:

Pancreatitis Patient Impact

Innovative Scientific Approach

Promising Market Returns

Mission:Cure

Guest Speaker



John Mellnik, PhD

- CEO, Path BioAnalytics

Path
BioAnalytics



PBA is a company
focused on **precision
drug development** for
under-served patient
communities


**Precision
medicine** looks
at the genetics,
environment,
and lifestyle of a
person in order
to develop drugs
that could work
best for them.

Mission:Cure

Path BioAnalytics



Translation is the process of **turning observations** in the laboratory **into interventions** that improve health outcomes of **individuals**



Drug **discovery** and **development** company using artificial intelligence and high-throughput biology to deliver better medicine through translational science




The company combines primary cells and 3D cell culture (organoid) technology to create **detailed, translational data** sets that reveal new insights about disease progression.

Mission:Cure

What Does This Mean For Pancreatitis Patients?

- Using PBA's proprietary technology and translational science to develop medicines to **treat or cure pancreatitis**
- Identifying drugs that will correct the problems in the pancreas caused by mutations in the CFTR gene*


***CFTR gene mutations** are the most common genetic cause of pancreatitis and may affect nearly 50% of cases in the US



A class of drugs called **CFTR modulators** target specific defects in the CFTR protein so that the protein can work properly.


Mission:Cure

Organoids from healthy individual




The CFTR protein is **fully functioning**, allowing fluid to move into the organoids, causing them to swell.

Organoid from individual with CFTR-pancreatitis



The **CFTR protein does not work** well, preventing fluid from moving into the organoid. **No swelling** happens.


Organoid from individual with CFTR pancreatitis after treatment



Function of the CFTR protein **has been corrected** by exposing the organoid to a drug, which **restores the swelling** behavior.

Mission:Cure

Guest Speakers



Dena Cohen

- CSO, Regenerative Medical Solutions



RMS is a company operating in Madison, Wisconsin working to **find a cure for all types of diabetes.**

Their experts have extensive experience in **stem cell development, pancreatic islet biology, and islet transplantation.**



Tony Kolton

- CEO, Regenerative Medical Solutions

Mission:Cure

Regenerative Medical Solutions


Vision

- To harness the regenerative property of human induced pluripotent stem cells (iPSCs) to **cure Type 1, Type 2 and Type 3C diabetes**

Technology

- Proprietary technology to **transform stem cells into islet-like cell clusters** that contain glucagon producing alpha cells, somatostatin producing delta cells and insulin producing β islet cells.

Mission:Cure



Islet cells are responsible for the production and release of hormones that regulate **glucose** levels

Need for New Diabetes Treatments


- Innovative approach replaces the beta cells destroyed by **Type 1, 2 or 3c diabetes** or as a result of **pancreatic surgery** such as TPIAT
- One concern about TPIAT is that it **may result in insulin-dependent diabetes**. Over 60% of TPIAT patients develop insulin dependence over time.
- RMS's patented technology **uses the patient's own cells** avoiding the need for immunosuppressants that current donor transplants require



RMS's patented technology will address the needs of patients with **all types of diabetes**

Mission:Cure

Personalized, cell-based therapy for diabetes



Regenerative Medical Solutions



Dr. Odorico is certified by the American Board of Surgery and specializes in **pancreas transplants, islet cell transplants** and **multi-organ transplants**.

He serves as Director of both the **Pancreas** and **Islet Transplantation Programs** at the Wisconsin-Madison School of Medicine and Public Health.

Jon Odorico, MD, FACS

- Scientific Founder

Mission:Cure



www.mission-cure.org



info@mission-cure.org



TWITTER
[@mission-cure](https://twitter.com/mission-cure)



FACEBOOK
[@MissionCureCP](https://www.facebook.com/MissionCureCP)



INSTAGRAM
[@mission-cure](https://www.instagram.com/mission-cure)

Mission:Cure

Contact



Mission Cure Capital
INVESTING TO CURE PANCREATITIS



lmartin@missioncurecapital.com



RMS
REGENERATIVE MEDICAL SOLUTIONS



info@regenmedsolutions.com

**Path
BioAnalytics**



info@pathbioanalytics.com

Mission:Cure